<?xml version='1.0' encoding='utf-8'?>
<document id="28991531"><sentence text="Identification of human cytochrome P450 and UGT enzymes involved in the metabolism of ferulic acid, a major bioactive component in traditional Chinese medicines."><entity charOffset="86-98" id="DDI-PubMed.28991531.s1.e0" text="ferulic acid" /></sentence><sentence text="Ferulic acid (FA) is an active component of herbal medicines"><entity charOffset="0-12" id="DDI-PubMed.28991531.s2.e0" text="Ferulic acid" /><entity charOffset="14-16" id="DDI-PubMed.28991531.s2.e1" text="FA" /><pair ddi="false" e1="DDI-PubMed.28991531.s2.e0" e2="DDI-PubMed.28991531.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28991531.s2.e0" e2="DDI-PubMed.28991531.s2.e1" /></sentence><sentence text=" One of the best documented activities of FA is its antioxidant property"><entity charOffset="42-44" id="DDI-PubMed.28991531.s3.e0" text="FA" /></sentence><sentence text=" Moreover, FA exerts antiallergic, anti-inflammatory, and hepatoprotective effects"><entity charOffset="11-13" id="DDI-PubMed.28991531.s4.e0" text="FA" /></sentence><sentence text=" However, the metabolic pathways of FA in humans remain unclear"><entity charOffset="36-38" id="DDI-PubMed.28991531.s5.e0" text="FA" /></sentence><sentence text=" To identify whether human CYP or UGT enzymes are involved in the metabolism of FA, reaction phenotyping of FA was conducted using major CYP-selective chemical inhibitors together with individual CYP and UGT Supersomes"><entity charOffset="80-82" id="DDI-PubMed.28991531.s6.e0" text="FA" /><entity charOffset="108-110" id="DDI-PubMed.28991531.s6.e1" text="FA" /><pair ddi="false" e1="DDI-PubMed.28991531.s6.e0" e2="DDI-PubMed.28991531.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28991531.s6.e0" e2="DDI-PubMed.28991531.s6.e1" /></sentence><sentence text=" The CYP- and/or UGT-mediated metabolism kinetics were examined simultaneously or individually" /><sentence text=" Relative activity factor and total normalized rate approaches were used to assess the relative contributions of each major human CYPs towards the FA metabolism"><entity charOffset="147-148" id="DDI-PubMed.28991531.s8.e0" text="FA" /></sentence><sentence text=" Incubations of FA with human liver microsomes (HLM) displayed NADPH- and UDPGA-dependent metabolism with multiple CYP and UGT isoforms involved"><entity charOffset="16-18" id="DDI-PubMed.28991531.s9.e0" text="FA" /><entity charOffset="63-69" id="DDI-PubMed.28991531.s9.e1" text="NADPH-" /><pair ddi="false" e1="DDI-PubMed.28991531.s9.e0" e2="DDI-PubMed.28991531.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28991531.s9.e0" e2="DDI-PubMed.28991531.s9.e1" /></sentence><sentence text=" CYPs and UGTs contributed equally to the metabolism of FA in HLM"><entity charOffset="56-58" id="DDI-PubMed.28991531.s10.e0" text="FA" /></sentence><sentence text=" Although CYP1A2 and CYP3A4 appeared to be the major contributors in the CYP-mediated clearance, their contributions to the overall clearance are still minor (&lt; 25%)" /><sentence text=" As a constitute of many food and herbs, FA poses low drug-drug interaction risk when co-administrated with other herbs or conventional medicines because multiple phase I and phase II enzymes are involved in its metabolism"><entity charOffset="41-42" id="DDI-PubMed.28991531.s12.e0" text="FA" /></sentence><sentence text="" /></document>